Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre.

IF 3.3 2区医学 Q2 ENDOCRINOLOGY & METABOLISM

Pituitary Pub Date : 2025-04-21 DOI:10.1007/s11102-025-01517-0

Ross Hamblin, Mary White, Athanasios Fountas, Niki Karavitaki

{"title":"Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre.","authors":"Ross Hamblin, Mary White, Athanasios Fountas, Niki Karavitaki","doi":"10.1007/s11102-025-01517-0","DOIUrl":null,"url":null,"abstract":"Purpose: Studies from various countries raise concerns on the association between dopamine agonist (DA) treatment and impulse control disorders (ICDs) in patients with pituitary adenomas. We investigated the prevalence of ICDs in patients with pituitary adenomas in a UK centre using two instruments applied in clinical practice for assessing ICDs.Methods: Cross-sectional study of adults with prolactinoma, acromegaly or non-functioning pituitary adenoma (NFPA) treated or not with DAs in a pituitary centre. Screening tools for ICD were the Minnesota Impulse Disorders Interview (MIDI) and Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale (QUIP-RS).Results: Data from 200 patients were analysed [72 prolactinomas (on DA), 71 NFPAs (no DA), 57 with acromegaly (12 on DA)]. The percentage of patients scoring for any ICD was higher in the prolactinoma on DA group compared with the NFPA cases; MIDI 12.7% vs. 1.4% (p = 0.02) and QUIP-RS 46.5% vs. 18.6% (p < 0.001), respectively. DA use was associated with positive scores for all ICDs in the MIDI and with compulsive buying and hobbyism-punding in the QUIP-RS. DA dose or treatment duration were not associated with positive scores. The responses of patients with acromegaly on DA did not differ from those not on these agents in any questionnaire.Conclusions: In this sample of UK patients, prevalence of ICDs is higher in prolactinoma patients on DA compared to those with NFPA not on DA. Differences were not observed between patients with acromegaly treated or not with DA. Different ICD assessment tools have an impact on the detected outcomes.","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":"28 3","pages":"52"},"PeriodicalIF":3.3000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12011938/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pituitary","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11102-025-01517-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Studies from various countries raise concerns on the association between dopamine agonist (DA) treatment and impulse control disorders (ICDs) in patients with pituitary adenomas. We investigated the prevalence of ICDs in patients with pituitary adenomas in a UK centre using two instruments applied in clinical practice for assessing ICDs.

Methods: Cross-sectional study of adults with prolactinoma, acromegaly or non-functioning pituitary adenoma (NFPA) treated or not with DAs in a pituitary centre. Screening tools for ICD were the Minnesota Impulse Disorders Interview (MIDI) and Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale (QUIP-RS).

Results: Data from 200 patients were analysed [72 prolactinomas (on DA), 71 NFPAs (no DA), 57 with acromegaly (12 on DA)]. The percentage of patients scoring for any ICD was higher in the prolactinoma on DA group compared with the NFPA cases; MIDI 12.7% vs. 1.4% (p = 0.02) and QUIP-RS 46.5% vs. 18.6% (p < 0.001), respectively. DA use was associated with positive scores for all ICDs in the MIDI and with compulsive buying and hobbyism-punding in the QUIP-RS. DA dose or treatment duration were not associated with positive scores. The responses of patients with acromegaly on DA did not differ from those not on these agents in any questionnaire.

Conclusions: In this sample of UK patients, prevalence of ICDs is higher in prolactinoma patients on DA compared to those with NFPA not on DA. Differences were not observed between patients with acromegaly treated or not with DA. Different ICD assessment tools have an impact on the detected outcomes.

查看原文本刊更多论文

使用或不使用多巴胺激动剂治疗垂体腺瘤患者的冲动控制障碍：来自英国中心的横断面研究。

目的：各国的研究对多巴胺激动剂（DA）治疗与垂体腺瘤患者冲动控制障碍（ICDs）之间的关系提出了关注。我们在英国的一个中心调查了垂体腺瘤患者中icd的患病率，使用了两种用于临床实践的仪器来评估icd。方法：横断面研究成人催乳素瘤，肢端肥大症或无功能垂体腺瘤（NFPA）在垂体中心治疗或不使用DAs。ICD的筛查工具是明尼苏达冲动障碍访谈（MIDI）和帕金森病冲动强迫症评定量表（QUIP-RS）问卷。结果：分析了200例患者的数据[72例泌乳素瘤（DA）， 71例nfpa（未DA）， 57例肢端肥大症（12例DA）]。与NFPA病例相比，DA组泌乳素瘤中任何ICD评分的患者百分比更高；MIDI 12.7% vs. 1.4% (p = 0.02), QUIP-RS 46.5% vs. 18.6% (p)。结论：在英国患者样本中，接受DA治疗的泌乳素瘤患者的icd患病率高于未接受DA治疗的NFPA患者。肢端肥大症患者与未接受DA治疗的患者之间无差异。不同的ICD评估工具会对检测到的结果产生影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pituitary 医学-内分泌学与代谢

CiteScore

7.10

自引率

7.90%

发文量

审稿时长

6 months

期刊介绍： Pituitary is an international publication devoted to basic and clinical aspects of the pituitary gland. It is designed to publish original, high quality research in both basic and pituitary function as well as clinical pituitary disease. The journal considers: Biology of Pituitary Tumors Mechanisms of Pituitary Hormone Secretion Regulation of Pituitary Function Prospective Clinical Studies of Pituitary Disease Critical Basic and Clinical Reviews Pituitary is directed at basic investigators, physiologists, clinical adult and pediatric endocrinologists, neurosurgeons and reproductive endocrinologists interested in the broad field of the pituitary and its disorders. The Editorial Board has been drawn from international experts in basic and clinical endocrinology. The journal offers a rapid turnaround time for review of manuscripts, and the high standard of the journal is maintained by a selective peer-review process which aims to publish only the highest quality manuscripts. Pituitary will foster the publication of creative scholarship as it pertains to the pituitary and will provide a forum for basic scientists and clinicians to publish their high quality pituitary-related work.